| Outcome Measures: |
Primary: Change in HbA1c, Change in HbA1c (%) between baseline and last measured value at 3 to 6 months follow-up, 3 to 6 months | Secondary: Change in body weight, Change in body weight (kg) between baseline and last measured value at 3 to 6 months follow-up, 3 to 6 months|Change in body mass index (BMI), Change in BMI (kg/m2) between baseline and last measured value at 3 to 6 months follow-up, 3 to 6 months|Change in systolic blood pressure (SBP), Change in SBP (mmHg) between baseline and last measured value at 3 to 6 months follow-up, 3 to 6 months|Change in diastolic blood pressure (DBP), Change in DBP (mmHg) between baseline and last measured value at 3 to 6 months follow-up, 3 to 6 months|Change in triglycerides, Change in triglycerides (mmol/L) between baseline and last measured value at 3 to 6 months follow-up, 3 to 6 months|Change in LDL cholesterol, Change in LDL cholesterol (mmol/L) between baseline and last measured value at 3 to 6 months follow-up, 3 to 6 months|Change in non-HDL cholesterol, Change in non-HDL cholesterol (mmol/L) between baseline and last measured value at 3 to 6 months follow-up, 3 to 6 months|Change in estimated glomerular filtration rate (eGFR), Change in eGFR (mL/min/1.73 m2) between baseline and last measured value at 3 to 6 months follow-up, 3 to 6 months|Change in alanine amino transaminase (ALT), Change in ALT (U/L) between baseline and last measured value at 3 to 6 months follow-up, 3 to 6 months|Proportion of patients who report ≥ 1 weekly incidence of any hypoglycemia, Analyses will also be stratified by sulfonylurea (SU) versus non-SU use, and insulin versus non-insulin use, 3 to 6 months|Proportion of patients who report ≥ 1 yearly incidence of severe hypoglycemia, Analyses will also be stratified by SU versus non-SU use, and insulin versus non-insulin use, 3 to 6 months|Proportion of patients who achieve HbA1c ≤7.0%, HbA1c will be the last measured value at 3 to 6 months follow-up, 3 to 6 months|Proportion of patients who achieve HbA1c ≤8.0%, HbA1c will be the last measured value at 3 to 6 months follow-up, 3 to 6 months|Proportion of patients who achieve HbA1c reduction ≥0.5%, HbA1c will be the last measured value at 3 to 6 months follow-up, 3 to 6 months|Proportion of patients who achieve HbA1c reduction ≥1.0%, HbA1c will be the last measured value at 3 to 6 months follow-up, 3 to 6 months|Proportion of patients who achieve weight loss ≥5%, Weight will be the last measured value at 3 to 6 months follow-up, 3 to 6 months|Proportion of patients who achieve weight loss ≥10%, Weight will be the last measured value at 3 to 6 months follow-up, 3 to 6 months | Other: Time to addition of another diabetes therapy, Number of weeks until addition of another diabetes therapy, 3 to 6 months|Time to discontinuation of GLP-1 RA therapy, Number of weeks until discontinuation of semaglutide therapy in patients who discontinue semaglutide during the follow-up period, 3 to 6 months|Insulin dose at baseline and follow-up, Insulin dose will be evaluated in the subgroup of patients using insulin therapy, 3 to 6 months|HbA1c change in low dose therapy and high dose therapy subgroups, Low dose therapy (semaglutide 0.5 mg) and full dose therapy (semaglutide 1.0 mg), 3 to 6 months|Body weight change in low dose therapy and high dose therapy subgroups, Low dose therapy (semaglutide 0.5 mg) and full dose therapy (semaglutide 1.0 mg), 3 to 6 months|HbA1c change in patients who discontinue a dipeptidyl peptidase-4 inhibitor (DPP-4i) at baseline versus simple addition of semaglutide, 3 to 6 months|Body weight change in patients who discontinue a DPP-4i at baseline versus simple addition of semaglutide, 3 to 6 months|HbA1c change in patients who discontinue any diabetes therapy at baseline versus simple addition of semaglutide, 3 to 6 months|Body weight change in patients who discontinue any diabetes therapy at baseline versus simple addition of semaglutide, 3 to 6 months|HbA1c change in insulin users and non-insulin users, Based on insulin therapy used at baseline, 3 to 6 months|Weight change in insulin users and non-insulin users, Based on insulin therapy used at baseline, 3 to 6 months|HbA1c change in patients who have a 13-week follow-up versus a 26-week follow-up, 3 to 6 months|Weight change in patients who have a 13-week follow-up versus a 26-week follow-up, 3 to 6 months|HbA1c change in patients prescribed semaglutide as second line therapy (excluding insulin use), In the subgroup of patients using one oral diabetes therapy at baseline, 3 to 6 months|Weight change in patients prescribed semaglutide as second line therapy (excluding insulin use), In the subgroup of patients using one other diabetes therapy at baseline, 3 to 6 months|HbA1c change in patients prescribed semaglutide as third line therapy (excluding insulin use), In the subgroup of patients using two oral diabetes therapies at baseline, 3 to 6 months|Weight change in patients prescribed semaglutide as third line therapy (excluding insulin use), In the subgroup of patients using two oral diabetes therapies at baseline, 3 to 6 months|HbA1c change in patients prescribed semaglutide as fourth line therapy (excluding insulin use), In the subgroup of patients using three oral diabetes therapies at baseline, 3 to 6 months|Weight change in patients prescribed semaglutide as fourth line therapy (excluding insulin use), In the subgroup of patients using three oral diabetes therapies at baseline, 3 to 6 months
|
